- Home
- ADEA vs DVAX Comparison
ADEA vs DVAX Comparison
Compare ADEA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- DVAX
- Stock Information
- Founded
- ADEA 1990
- DVAX 1996
- Country
- ADEA United States
- DVAX United States
- Employees
- ADEA N/A
- DVAX N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- ADEA Technology
- DVAX Health Care
- Exchange
- ADEA Nasdaq
- DVAX Nasdaq
- Market Cap
- ADEA 1.5B
- DVAX 1.7B
- IPO Year
- ADEA N/A
- DVAX 2004
- Fundamental
- Price
- ADEA $13.25
- DVAX $12.68
- Analyst Decision
- ADEA Strong Buy
- DVAX Buy
- Analyst Count
- ADEA 2
- DVAX 2
- Target Price
- ADEA $17.00
- DVAX $23.00
- AVG Volume (30 Days)
- ADEA 581.6K
- DVAX 1.7M
- Earning Date
- ADEA 02-18-2025
- DVAX 02-20-2025
- Dividend Yield
- ADEA 1.53%
- DVAX N/A
- EPS Growth
- ADEA N/A
- DVAX N/A
- EPS
- ADEA 0.37
- DVAX 0.15
- Revenue
- ADEA $343,723,000.00
- DVAX $260,810,000.00
- Revenue This Year
- ADEA N/A
- DVAX $22.13
- Revenue Next Year
- ADEA $8.69
- DVAX $19.91
- P/E Ratio
- ADEA $34.91
- DVAX $83.61
- Revenue Growth
- ADEA N/A
- DVAX N/A
- 52 Week Low
- ADEA $9.68
- DVAX $9.74
- 52 Week High
- ADEA $14.75
- DVAX $14.30
- Technical
- Relative Strength Index (RSI)
- ADEA 48.90
- DVAX 50.85
- Support Level
- ADEA $12.74
- DVAX $12.21
- Resistance Level
- ADEA $13.26
- DVAX $12.74
- Average True Range (ATR)
- ADEA 0.39
- DVAX 0.36
- MACD
- ADEA -0.13
- DVAX -0.04
- Stochastic Oscillator
- ADEA 32.24
- DVAX 57.39
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property Licensing (IP). In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.